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How will Comparative Effectiveness Research Influence
Clinical Decision Making?
Nicholas Zaorsky, MD and Timothy Showalter, MD

Abstract
Most health care recommendations in the United States have
come from trials designed to measure efficacy of medical
interventions, with randomized controlled trials considered
the gold standard for evidence-based medicine. Comparative
effectiveness research has become an essential component of
research to help define the benefits, risks, and effectiveness of
different interventions for a particular illness. Comparative
effectiveness research is informally defined as an assessment of all
available options for a specific medical condition, with intent to
estimate effectiveness in specific subpopulations. In this article,
we contrast efficacy-based healthcare research and recommendations in the United States, under the model of evidencebased medicine, to the contemporary paradigm of comparative
effectiveness research. We review the recent emphasis by the
federal government on comparative effectiveness research.
Finally, we review the limitations of effectiveness and efficiency.

(I) What are the limitations behind current medical recommendations in the United States?
Currently, most healthcare recommendations in the United
States are based on studies designed to evaluate efficacy, which
measures whether one novel intervention could have an impact
on outcomes under ideal conditions.1 The gold standard of
proving efficacy is a randomized controlled trial (RCT). Trials
of efficacy have been crucial in the discovery of diagnostic tests,
medications, surgical instruments, and systems of medical
delivery.
However, medical recommendations based solely on efficacy are
limited for a number of reasons.1-3 The results of an efficacy trial
are aimed to provide a therapy for a homogenous population of
healthy participants under highly-controlled conditions, which
may not reflect the population heterogeneity seen in community
practice. Due to the long study periods of efficacy trials, published
results may be lagging behind the latest scientific research and
interventions, making trial results when an immediate medical
decision is necessary. As level I evidence from RCTs does not
always exist, recommendations are based rather on various
reviews of differing objectives, outcome measures, and study
qualities. In addition, testing for efficacy examines all potential
interventions that may have incremental benefits when no
proven therapy exists, thereby not aiding in practical medical
decision making between already accepted treatment options.
RCTs are usually limited to major academic institutions, which
have established databases and scientists devoted to publication
of the data. RCTs typically exclude smaller institutions and
private practices, which may serve patient subpopulations. These
patient subpopulations may not present to the large academic
institutions and may respond differently to a recommended
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therapy. The potential benefits at the clinical trial level do not
always translate to real-world improvements as well, when
other factors such as time and cost are factored in. Furthermore,
efficacy-based trials simply may not accrue enough patients to
answer a queried hypothesis. Finally, trials of efficacy are typically
expensive, precluding testing of other potential interventions
that may have incremental benefits. These limitations call for
complementary research that is designed to better inform the
clinical decision making process.

(II) What is comparative effective research?
Comparative effectiveness research (CER) is separate from and
complementary to research approaches that measure efficacy.
CER is informally defined as an assessment of available options
for treating specific medical conditions in selected groups
of patients. 4,5 CER focuses on treatment effectiveness, i.e.
whether the intervention makes an impact under “real-world”
conditions, and efficiency, i.e. whether an intervention is worth
the resources it consumes.1 The contemporary concept of CER
is to incorporate all available data to direct practitioners to
optimal patient-specific treatment decisions. Studies in CER
are recommended to: (1) influence clinical decision making by
identifying the most effective health care options where clear
options exist, (2) support the development of personalized
or stratified medicine by examining the racial, ethnic,
socioeconomic, and geographic variations in care that affect
health outcomes, (3) find the clinical characteristics that predict
which intervention would be most successful in an individual
patients, (4) integrate outcome measures, including patientreported quality of life and costs to patients and providers, and
(5) link data from public and private entities.2,5-9 Examples of
CER studies are now present throughout medicine and include
research designed to evaluate the effectiveness of medical
interventions in cardiology, endocrinology, medical oncology,
radiation oncology, and psychiatry.10-15
CER also focuses on targeting specific patient subpopulations
through predictive biomarkers and companion diagnostics.16,17
Predictive biomarkers are baseline characteristics that categorize
patients by their likelihood of responding to a particular
treatment, including favorable and unfavorable responses.
Examples of predictive biomarkers include Apolipoprotein E4
(APOE4) status in Alzheimer’s patients and Human Epidermal
growth factor Receptor 2 (HER2) overexpression in breast cancer
patients.18,19 Companion diagnostics are predictive biomarkers
that are developed into commercially available diagnostic tests,
such as Oncotype DX for breast cancer.17
Biomarker-specific therapeutic interventions are combined with
companion diagnostics to target a patient subpopulation for
treatment. The combination of one therapy with one biomarker
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is the sine qua non of ‘personalized’ stratified medicine. By
targeting patients on the basis of biomarkers, patient subpopulations that respond differently to treatment are identified,
thereby generating more favorable benefit–risk profiles for
the therapeutic. This is in contrast to the traditional empirical
‘all-comers’ approach of efficacy-based trials, where any patients
with the disease of interest may be enrolled. 20 Estimates of
treatment effect size that are limited to biomarker-expressing
patient subpopulations may better reflect the impact of a
candidate therapeutic agent. Moreover, trials limited to patient
subpopulations avoid exposure of others to a drug since these
individuals would lack the predictive biomarker. CER may
therefore strengthen the ability to measure effect and improve
patient safety.

(III) Quantifying the success of comparative effectiveness
research
The expected net present value (eNPV) has been used to estimate
the potential success of medical studies including comparative
effectiveness trials.20,21 The eNPV is the risk-adjusted sum of the
value of an investment or project. It integrates the costs necessary
to undertake a potential project (e.g. cost to develop a clinical
test, timing of development and approval, time to physician
adoption) to the potential monetary benefits (e.g. the sales and
lifetime gross profit of a test).21 Companies tend to fund projects
that have a positive eNPV because it indicates a value-adding
investment.20,22 With substantial prior confidence in predictive
biomarkers, a stratified medicine development strategy often
generates a higher eNPV than an ‘all-comers’ approach.
The eNPV has been used to estimate the potential success of
medical studies.20 For example, in oncology, eNPV modeling
studies for HER2, the biomarker used for response to the drug
trastuzumab, mirrored the actual benefits of trastuzumab in
clinical trials that included patients expressing HER2. 16,23, 24 In
neurology, eNPV modeling studies have shown that prospective
stratified medicine approaches that identify patients positive for
APOE4, the candidate biomarker for bapineuzumab, created a
six-time greater eNPV value than the traditional approach of
using bapineuzumab on all Alzheimer’s patients.16 In these eNPV
modeling studies, patient subpopulations that would respond
best to a therapy were identified. The eNPV of conducting trials
for therapies aimed directly at the subpopulations mirrored the
actual successes of the trials.

(IV) The impetus behind comparative effectiveness research in
the United States
CER is not a novel idea, but the United States government has
recently provided a new push for CE.25 In recognition of the
value in CER research, the American Recovery and Reinvestment
Act of 2009 allocated $1.1 billion to toward CER and the
Patient Protection and Affordable Care Act of 2010 created the
Patient Centered Outcomes Research Institute (PCORI) with
an estimated $600 million yearly funding to pursue CER. 26
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Both PCORI and the Agency for Healthcare Research and
Quality (AHRQ) define CER as research “designed to inform
health-care decisions by providing evidence on the effectiveness,
benefits, and harms of different treatment options. The evidence
is generated from research studies that compare drugs, medical
devices, tests, surgeries, or ways to deliver health care.”27
Controversy persists on whether costs of care should be included
as a component of CER. Based on the guidelines of PCORI and
the Centers for Medicare and Medicaid Services, cost will not
be considered in reimbursement or in investigations of CER,
and cost per quality adjusted life years analyses are specifically
prohibited. However, in the current budget climate and limited
medical resources, cost has become an important consideration,
if not officially sanctioned. Unofficially, CER studies include
analyses of the economic impact of potential interventions with
cost-effective and cost-benefit analyses.28,29

(V) CER follows studies that establish efficacy
CER will be crucial for the treatment of patients with known
biomarkers and multiple modalities of therapy available.
Nonetheless, dynamic interactions exist among the prevalence
of predictive biomarkers, the clinical performance of the
companion diagnostic, and the effect of a therapy. 16 First,
if a therapy has a rapid efficacy onset and acceptable safety
profile, the predictive biomarkers may not be necessary since
a physician may rapidly determine therapeutic response.20
Second, if the companion diagnostic is not widely distributed,
then it will be impossible to screen for a biomarker. Third, the
need to screen more patients with a companion diagnostic may
lengthen the duration of a study. Prospective RCTs will still be
necessary to validate the companion diagnostic and establish the
predictive value, which would increase the cost of development
and negate potential savings. Fourth, treatment response of
a biomarker-specific therapy may not correlate strongly with
biomarker expression, as was the case with EGFR expression and
cetuximab, where the expression of EGFR did not correlate with
the expected benefit in progression-free or overall survival.30 If
a companion diagnostic does not already exist for a disorder, its
development adds to the risk of failure and a negative eNPV.
Further, information regarding the prevalence of a biomarker
may not be available in a large database of patients, precluding
the use of that therapy. Finally, biomarker-specific therapies
face restricted pricing flexibility for their use in a smaller patient
population.16 If there are fewer people who could benefit from
the drug, the company providing the drug must tailor the price
for these individuals. Thus, studies of effectiveness or efficiency
are not always feasible, while studies of efficacy continue to be
important in innovation and population medicine.

Conclusion
Current health care recommendations in the United States
have mostly come from trials of efficacy, which ask if a therapy
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could work in an ideal situation. In contrast, CER focuses on
whether an intervention makes an impact under “real-world”
conditions (its effectiveness) and if an intervention is worth the
resources it consumes (its efficiency). CER integrates the use
of predictive biomarkers and companion diagnostics to predict
which intervention would be most successful in an individual
patient. The eNPV of such studies is higher than that of efficacybased RCTs, and the US government has recently provided a
financial impetus for increasing CER. Nonetheless, CER has
elicited concerns for a variety of reasons, including methodological challenges, choice of appropriate comparator, lack of
biomarker data in large databases, and lack of existing efficacy
trials. The push toward CER represents an extension of research
resources beyond the traditional biomedical research model of
evidence-based medicine, in which carefully-designed RCTs to
measure efficacy reign supreme. Future health care recommendations will come from studies of effectiveness and efficiency.
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